| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 20% | 0% | $7,323,621 | +$1,040,860 | 10,613,944 | +17% | GILEAD SCIENCES, INC. | 30 Jun 2025 |
| Frazier Life Sciences Public Fund, L.P. | 9.9% | 0% | $5,617,302 | +$1,651,739 | 8,141,017 | +42% | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 |
| Point72 Asset Management, L.P. | 9.9% | +39% | $6,752,000 | +$3,376,000 | 8,000,000 | +100% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Coastlands Capital LP | 10% | $4,009,552 | 5,346,069 | Coastlands Capital LP | 04 Dec 2025 | |||
| AbbVie Inc. | 9% | $3,086,956 | 4,347,826 | AbbVie Inc. | 11 Feb 2025 | |||
| STEMPOINT CAPITAL LP | 7.2% | $3,376,000 | 4,000,000 | StemPoint Capital LP | 30 Sep 2025 |
As of 30 Sep 2025, 36 institutional investors reported holding 22,051,916 shares of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO). This represents 41% of the company’s total 53,514,204 outstanding shares.
The largest institutional shareholders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 17% | 9,105,451 | 0% | 0.43% | $7,673,164 |
| Bain Capital Life Sciences Investors, LLC | 8.5% | 4,566,817 | 0% | 0.26% | $3,848,457 |
| Merck & Co., Inc. | 2.8% | 1,483,758 | 0% | 0.55% | $1,250,363 |
| TAKEDA PHARMACEUTICAL CO LTD | 2.8% | 1,475,121 | 0% | 7.6% | $1,243,084 |
| VANGUARD GROUP INC | 2.3% | 1,255,692 | +9.1% | 0% | $1,058,549 |
| MORGAN STANLEY | 1.8% | 961,917 | -33% | 0% | $810,607 |
| AJU IB Investment Co., Ltd. | 1.2% | 667,742 | 0% | 0.52% | $595,559 |
| FMR LLC | 0.96% | 511,820 | 0% | 0% | $431,311 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.61% | 328,972 | -11% | 0% | $277,257 |
| Squarepoint Ops LLC | 0.61% | 328,794 | +40% | 0% | $277,075 |
| Trustees of Columbia University in the City of New York | 0.47% | 249,635 | 0% | 0.03% | $210,442 |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 204,700 | +25% | 0% | $172,501 |
| Balyasny Asset Management L.P. | 0.37% | 198,859 | 0% | 0% | $167,578 |
| STATE STREET CORP | 0.31% | 163,890 | +278% | 0% | $138,110 |
| TWO SIGMA INVESTMENTS, LP | 0.16% | 87,790 | +13% | 0% | $73,981 |
| XTX Topco Ltd | 0.14% | 76,045 | +119% | 0% | $64,083 |
| NORTHERN TRUST CORP | 0.12% | 66,609 | 0% | 0% | $56,131 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.1% | 56,081 | 0% | 0% | $47,259 |
| TWO SIGMA SECURITIES, LLC | 0.06% | 32,130 | 0% | $27,076 | |
| LPL Financial LLC | 0.06% | 31,000 | 0% | 0% | $26,124 |
| TWO SIGMA ADVISERS, LP | 0.06% | 29,689 | 0% | $25,019 | |
| Aptus Capital Advisors, LLC | 0.05% | 25,000 | 0% | 0% | $21,068 |
| SevenBridge Financial Group, LLC | 0.05% | 25,000 | 0% | 0% | $19,333 |
| Mariner, LLC | 0.05% | 25,000 | 0% | 0% | $21,068 |
| HRT FINANCIAL LP | 0.05% | 24,736 | 0% | $20,000 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 22,051,916 | $18,613,906 | -$1,227,313 | $0.84 | 36 |
| 2025 Q2 | 23,795,263 | $16,179,092 | +$854,218 | $0.68 | 35 |
| 2025 Q1 | 22,528,206 | $16,318,555 | -$3,181,066 | $0.72 | 35 |
| 2024 Q4 | 25,814,355 | $24,660,128 | -$144,644 | $0.96 | 34 |
| 2024 Q3 | 15,911,945 | $12,534,583 | +$1,128,158 | $0.79 | 32 |
| 2024 Q2 | 13,033,702 | $12,347,801 | +$1,785,266 | $0.95 | 30 |
| 2024 Q1 | 12,460,895 | $13,460,257 | -$2,778,261 | $1.08 | 30 |
| 2023 Q4 | 1,475,121 | $811,316 | $0.55 | 1 | |
| 2023 Q3 | 15,860,160 | $33,465,952 | -$314,934 | $2.11 | 30 |
| 2023 Q2 | 16,002,286 | $41,925,598 | -$192,248 | $2.62 | 32 |
| 2023 Q1 | 16,072,057 | $50,979,505 | +$461,643 | $3.17 | 32 |
| 2022 Q4 | 15,926,513 | $42,841,966 | -$711,172 | $2.69 | 28 |
| 2022 Q3 | 16,560,472 | $48,193,000 | -$3,735,663 | $2.91 | 26 |
| 2022 Q2 | 17,824,055 | $52,046,910 | -$2,927,686 | $2.92 | 26 |
| 2022 Q1 | 18,775,939 | $132,746,000 | -$2,569,964 | $7.07 | 41 |
| 2021 Q4 | 18,991,382 | $303,129,000 | +$258,979,068 | $16.00 | 41 |